Meet our team
Predictive Oncology
Corporate Leadership

Raymond F. Vennare
Chief Executive Officer
and Chairman of the Board
Raymond F. Vennare became Predictive Oncology’s CEO and Chairman of the Board on November 1, 2022. He has served on the Board of Directors since September of 2021.
![POAI Headshot[52] POAI Headshot[52]](https://predictive-oncology.com/wp-content/uploads/elementor/thumbs/POAI-Headshot52-e1696341531685-qy1rhrlzxwbn5ivni74jp2zvqx7ghp2c5nub6ca1xg.jpg)
Josh Blacher, MBA
Interim Chief Financial Officer
Josh Blacher, MBA is the Interim Chief Financial Officer for Predictive Oncology. As a strategic and operational CFO with more than 20 years of experience in leadership for private and Nasdaq-listed companies, Mr. Blacher specializes in the life science and biotech sectors.

Arlette H. Uihlein, MD
SVP, Translational Medicine and Drug Discovery, Medical Director
Arlette H. Uihlein, MD, FCAP, FASCP, is Senior Vice President of Translational Medicine and Drug Discovery for Predictive Oncology and Site Leader of Helomics. She has also served as Medical Director of Helomics® Clinical and Research Labs since 2011.
Let’s discover and develop together.
We want to hear about your process challenges—and identify ways to solve them together. Complete the form to get in touch with our team of experts.
News & resources
Drug repurposing using the Predictive Oncology machine learning approach and proprietary biobank of frozen dissociated tumor cells (DTCs) is outlined in this new white paper....Learn more
Following the generation of successful results with the University of Michigan through the ACE program, Predictive Oncology is now actively calling for submissions for a...Learn more
This Executive Overview outlines the proof-of-concept study completed by Predictive Oncology to illustrate the power of our active machine learning (AI) platform paired with our...Learn more